|
|
|
| An Analysis of the Association Between Serum Tumor Markers Levels and Pathological Features and Prognosis in Patients with Ovarian Cancer |
| XING Huarui, FENG Yani, LI Xiaofang, et al |
| Qionghai Hospital of Traditional Chinese Medicine, Hainan Qionghai 571400, China |
|
|
|
|
Abstract Objective: To study the serum levels of human epididymis protein 4 (HE4), cancer antigen 125 (CA125) and chitinase protein 40 (YKL-40) in patients with ovarian cancer and their association with pathological features and prognosis. Methods: A total of 92 patients with ovarian masses who underwent surgery in Qionghai Hospital of traditional Chinese Medicine from January 2016 to August 2019 were included in the study. According to the results of surgical pathology, they were divided into benign group (n=52) and malignant group (n=40). The levels of serum HE4, CA125 and YKL-40 were compared between the two groups. The relationship between serum HE4, CA125 and YKL-40 levels and different pathological features was analyzed in patients with ovarian cancer. The survival curves of the subjects were plotted to analyze the association between postoperative serum HE4, CA125 and YKL-40 levels and prognosis of patients. Results: The serum levels of HE4, CA125 and YKL-40 in malignant group were significantly higher than those in benign group (P<0.05). The serum HE4 level in patients with ovarian cancer was correlated with pathological tissue types and lymphatic metastasis (P<0.05), and serum CA125 was correlated with operation staging, tissue types, lymphatic metastasis and age (P<0.05), and serum YKL-40 was correlated with operation staging and lymphatic metastasis (P<0.05). The serum levels of HE4, CA125 and YKL-40 after operation in patients with ovarian cancer were significantly lower than those before operation (P<0.001). According to the median method, patients with ovarian cancer were divided into postoperative serum HE4 high-level group (n=17) and low-level group (n=23), CA125 high-level group (n=15) and low-level group (n=25), YKL-49 high-level group (n=22) and low-level group (n=18). The survival curves of the subjects found there was no significant difference in the survival curve of patients with postoperative serum HE4 high-level and low-level (χ2=2.42, P>0.05), and there was a significant difference in the survival curve of patients with serum CA125 high-level and low-level (χ2=4.12, P<0.05), and there was no significant difference in the survival curve of patients with serm YKL-40 high-level and low-level (χ2=1.94, P>0.05). Conclusion: The serum levels of HE4, YKL-40 and CA125 in patients with ovarian cancer can indicate the condition and prognosis of patients to some extent.
|
|
|
|
|
|
[1] 张爽爽, 夏庆民, 郑荣寿, 陈万青.中国2010年卵巢癌发病与死亡分析[J].中国肿瘤, 2016, 25(3):169~173.
[2] 刘海伦(综述), 程忠平(审校).CA125不同计算方法在卵巢癌筛查、评估及预后方面的作用[J].现代妇产科进展, 2016, 25(8):636~639.
[3] 谢文光, 林晓桃, 陈文锋.血清CA125、HE4检测及ROMA模型在恶性卵巢癌中的诊断价值[J].国际检验医学杂志, 2016, 37(24):3503~3504.
[4] 罗宏涛, 魏世鸿, 车团结, 等.乳腺癌放疗前后血清YKL-40浓度与临床特征关系的研究[J].中华肿瘤防治杂志, 2016, 23(15):1011~1015.
[5] 陈藕景, 祝莹.血清肿瘤标志物在卵巢癌早期诊断中的临床价值[J].中国性科学, 2016, 25(3):48~50.
[6] 王静, 王萍.卵巢癌肿瘤标志物的早期诊断价值研究新进展[J].河北北方学院学报(自然科学版), 2019, 35(12):58~61.
[7] 陈素云, 赵志清, 吕永革, 吴冬, 孙雄峰, 王开勇.MRI、HE4在卵巢交界性肿瘤与Ⅰ期卵巢癌鉴别诊断中的价值[J].中国医疗设备, 2019, 34(S1):100~102.
[8] 彭琼, 朱碧琳.血清人附睾分泌蛋白-4对上皮性卵巢癌的早期诊断价值研究[J].中国实验诊断学, 2018, 22(4):628~629.
[9] 陈明, 段淑荣, 刘盼月, 等.血清YKL-40与动脉粥样硬化性脑梗死的研究[J].脑与神经疾病杂志, 2017, 25(4):256~259.
[10] 程浩, 许军.YKL-40与乳腺癌预后的研究进展[J].中国现代普通外科进展, 2016, 19(1):39~41. |
|
|
|
2020, Vol. 26 
